Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05IPO
|
||||
| Former ID |
DCL000732
|
||||
| Drug Name |
BTS-79018
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Terminated | [1] | ||
| Company |
Abbott
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H27ClN2O3
|
||||
| Canonical SMILES |
COC1=CC=CC=C1N2CCC(CC2)CNCC3COC4=C(O3)C=C(C=C4)Cl
|
||||
| InChI |
1S/C22H27ClN2O3/c1-26-20-5-3-2-4-19(20)25-10-8-16(9-11-25)13-24-14-18-15-27-21-7-6-17(23)12-22(21)28-18/h2-7,12,16,18,24H,8-11,13-15H2,1H3
|
||||
| InChIKey |
QHLRKDSRGUZHSH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 170353-17-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Binder | [1] | |
| 5-hydroxytryptamine 1A receptor | Target Info | Binder | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Dopaminergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| SIDS Susceptibility Pathways | |||||
| References | |||||
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.